Barclays lowered the firm’s price target on Baxter (BAX) to $25 from $30 and keeps an Overweight rating on the shares. The company’s mixed Q4 results and negative earnings leverage in 2026 are a surprise, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter International Earnings Call: Growth Meets Margin Squeeze
- Baxter price target lowered to $19 from $21 at Jefferies
- Baxter price target lowered to $20 from $22 at Stifel
- Midday Fly By: Cisco reports Q2 beat, Trump orders Pentagon to buy coal
- Morning Movers: Fastly skyrockets following fourth quarter results